ArticleJournal of cancer research and clinical oncology2025
Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGiven the limited treatment options recommended for cancer of unknown primary (CUP), especially the role of immune checkpoint inhibitors (ICIs), our study aimed to evaluate the efficacy of ICIs and identify associated genomic biomarkers in these patients.
methodsThis retrospective, multicenter, real-world analysis included individuals with oncologist-confirmed CUP cases treated with ICIs across four hospitals in China. Clinical outcomes, safety and biomarkers were analyzed.
resultsBetween January 2016 and November 2023, 124 patients were enrolled. Of these, 117 patients underwent combination therapy, predominantly ICIs with taxane-platinum based chemotherapy (54.84%), while 7 received monotherapy. After a median follow-up of 18.6 months, the median progression free survival (PFS) and overall survival (OS) were 23.20 and 38.86 months, respectively. According to ESMO guideline, patients were stratified into favorable (n = 41) and unfavorable subset (n = 83). The favorable subset demonstrated significantly longer PFS and OS than the unfavorable subset (median PFS NR vs. 9.7 months, P < 0.001; median OS NR vs. 23.73 months, P < 0.001). There are 31 patients in our cohort whose PD-L1 detection results are available, while 25 patients was eligible for TMB assessment. Better clinical efficacy of ICIs was apparent for tumors with a higher PD-L1 expression (CPS ≥ 20) and a greater tumor mutation burden (> 12 mutations/Mb). Multivariate analyses revealed that higher ECOG performance status, the presence of visceral metastasis, and KRAS mutation were independently associated with inferior PFS and OS. Immune-related adverse events occurred in 49 (39.52%) patients, with one developing grade 3 pneumonia.
conclusionsThe application of ICIs showed encouraging efficacy with an acceptable safety profile, suggesting its potential as an additional therapeutic option for CUP patients. Identifying predictive markers for ICIs response remains essential to enhance therapeutic strategies in CUP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.